Biography
She is a physician-scientist who conducts extensive research. She completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program and she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. Her research focuses on studies evaluating strategies whereby donor T cells can be administered to improve outcomes following blood and marrow transplant. Specifically, she studies novel treatment strategies using chimeric antigen receptor (CAR) T cell therapy.
Dr. Smith has been invited to present the findings of her research at regional, national, and international conferences. At the Insights in Hematology Conference, she focused on the use of CAR T cells for blood cancers, whereas she presented her investigations on the associations between CAR T cells and the intestinal microbiome at the European Society for Blood and Marrow Transplantation. Further, at the annual meeting of the American Society of Gene & Cell Therapy, she addressed the importance of training scientists from underrepresented populations.
Dr. Smith has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, including Biology of Blood and Marrow Transplantation, Blood Advances, Leukemia, Nature, Nature Immunology, Nature Medicine, and elsewhere.
She serves a peer reviewer for publications in various journals, such as Biology of Blood and Marrow Transplantation, Haematologica, and ImmunoMedicine. She also has co-written chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
Dr. Smith has also earned numerous honors. The American Society of Hematology, Society for Immunotherapy of Cancer, European Society for Blood and Marrow Transplantation, and many other professional societies and organizations have recognized her achievements as a clinician, researcher, and scholar.
She is a member of the American Society of Hematology (ASH) Subcommittee on Immunotherapy and the co-chair of the Committee on Trainees and Junior Faculty for the American Society of Transplantation and Cellular Therapy (ASTCT). Other positions in service to professional organizations include co-chairing committees and task forces dedicated to promoting diversity among hematology and cell therapy specialists.
Professional Summary
Education & Certifications
- Board Certification, American Board of Internal Medicine, Medical Oncology
- Board Certification, American Board of Internal Medicine, Hematology
- Board Certification, American Board of Internal Medicine, Internal Medicine
- Fellowship, Memorial Sloan Kettering Cancer Center, Medical Oncology and Hematology
- Residency, University of Texas Southwestern Medical School, Internal Medicine
- Internship, University of Texas Southwestern Medical School, Internal Medicine
- Medical Education, University of Texas Southwestern Medical School
Honors & Awards
- 2nd Annual Mentoring Program for SCT Fellows, Future of Stem Cell Transplantation
- Abstract Achievement Award, American Society of Hematology (ASH)
- ASH Minority Medical Student Award, American Society of Hematology (ASH)
- ASH Translational Research Training in Hematology, European Hematology Association
- Best Basic Science Abstract, European Society for Blood and Marrow Transplantation
- Clinical Research Training Course, American Society for Blood and Marrow Transplantation (ASBMT)
- Loan Repayment Award, National Institutes of Health (NIH)
- Mechanistic Insights to Improve Clinical Benefit, Early Career Investigator Travel Award, Keystone Symposium on Cancer Immunotherapy
- Minority Faculty Leadership Development, Awarded Competitive Admission to American Association of Medical Colleges (AAMC)
- Resident Travel Award for Underrepresented Populations, Conquer Cancer Foundation of American Society of Clinical Oncology
- SITC Travel Award, 3rd Forum on Immunotherapy & Translational Immunology of Cancer
- Women in Cancer Immunotherapy Network (WIN) Leadership Institute, Society for Immunotherapy of Cancer (SITC)
Administrative Appointments
- Assistant Professor, Division of Blood & Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine (2021 - Present)
Publications
-
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.
Hamilton, B. K., Rybicki, L., Abounader, D., Adekola, K., Advani, A., Aldoss, I., … Majhail, N. S. (2017). Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation . -
Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen.
Vardhana, S. A., Hwee, M. A., Berisa, M., Wells, D. K., Yost, K. E., King, B., … Thompson, C. B. (2020). Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nature Immunology. -
A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma
Smith, M. (2021). A Question of Beneficence: Comorbidity Assessment to Ascertain Potential Benefit of CD19 Chimeric Antigen Receptor T Cells for Patients with Diffuse Large B Cell Lymphoma. TRANSPLANTATION AND CELLULAR THERAPY, 27(1), 2–3. -
Posttransplant chimeric antigen receptor therapy
Smith, M., Zakrzewski, J., James, S., & Sadelain, M. (2018). Posttransplant chimeric antigen receptor therapy. BLOOD, 131(10), 1045–1052. -
Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer
Page, D. B., Bourla, A. B., Daniyan, A., Naidoo, J., Smith, E., Smith, M., … Callahan, M. K. (2015). Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 3. -
The Composition of the Intestinal Microbiota Correlates with Response and Toxicity after CAR T cell Immunotherapy in Patients with B-cell Malignancies
Smith, M. (2021). The Composition of the Intestinal Microbiota Correlates with Response and Toxicity after CAR T cell Immunotherapy in Patients with B-cell Malignancies. Nature Medicine . -
Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109a induce less graft-versus-host disease
Smith, M. (2021). Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109a induce less graft-versus-host disease. Blood. -
Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy.
Smith, M. (2021). Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. . Transplantation and Cellular Therapy. -
The gut microbiota is associated with immune cell dynamics in humans
Schluter, J., Peled, J. U., Taylor, B. P., Markey, K. A., Smith, M., Taur, Y., … Xavier, J. B. (2020). The gut microbiota is associated with immune cell dynamics in humans. NATURE, 588(7837), 303–307. -
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., … Mailankody, S. (2020). Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. BLOOD ADVANCES, 4(15), 3776–3787. -
Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans
Masselink, L. E., Erikson, C. E., Connell, N. T., De Castro, L. M., Dent, G. A., Marshall, A. L., … Lee, A. I. (2019). Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans. BLOOD ADVANCES, 3(21), 3278–3286. -
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation
Scordo, M., Bhatt, V., Hilden, P., Smith, M., Thoren, K., Cho, C., … Giralt, S. A. (2019). Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(8), 1526–1535. -
Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Ghosh, A., Smith, M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., … van den Brink, M. R. M. (2017). Donor CD19 CART cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. NATURE MEDICINE, 23(2), 242–249. -
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
Landau, H., Smith, M., Landry, C., Chou, J. F., Devlin, S. M., Hassoun, H., … Comenzo, R. L. (2017). Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. LEUKEMIA, 31(1), 136–142. -
Both naive and memory T cells exert alloreactivity across HLA barriers
Smith, M. (2011). Both naive and memory T cells exert alloreactivity across HLA barriers. Biology of Blood and Marrow Transplantation. -
Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma
Smith, M. (2011). Clinical, Molecular, and Environmental Risk Factors for Hodgkin Lymphoma. Advances in Hematology. -
Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States
Shenoy, P. J., Malik, N., Sinha, R., Nooka, A., Nastoupil, L. J., Smith, M., & Flowers, C. R. (2011). Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 11(6), 498–506. -
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., … Ruella, M. (2022). Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. -
Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support.
Lee, A. I., Masselink, L. E., De Castro, L. M., Marshall, A. L., Connell, N. T., Dent, G. A., … Erikson, C. E. (2022). Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances. -
Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar, N., & Smith, M. (2022). Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. Frontiers in Immunology, 13, 887866.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CABlood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive
875 Blake Wilbur Drive, Clinic E, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records